Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LM-030 is the only program in clinical development for Netherton and could potentially become the first approved targeted therapy.
Lead Product(s): LM-030
Therapeutic Area: Rare Diseases and Disorders Product Name: LM-030
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2020